Aelin raises €27M in series A

On Dec. 11, Aelin Therapeutics N.V. (Leuven, Belgium) debuted with a €27 million ($31.8 million) series A round from LSP, PMV, Novartis Venture Fund, Boehringer Ingelheim Venture Fund and Fund+.

Aelin spun out of the Flanders Institute for Biotechnology (VIB) and its partner universities Catholic University Leuven, VIB-UGent and VIB-VUB. The newco is developing antibiotics and therapeutics based on its Pept-ins technology, which uses protein aggregation to design compounds that induce functional knockdown of intracellular target proteins typically out of reach for small molecule or antibody approaches. ...